616 results about "Pyridazine" patented technology

An active matrix display comprises a chiral smectic liquid crystal mixture which has the phase sequence I-N*-SmC*, a spontaneous polarization in the operating temperature range of <40 nC/cm2 and a pitch of >10 mum at at least one temperature in the nematic or cholesteric phase and comprises at least one compound each from at least two of the substance classes (A), (B) and (C) and one or more compounds from substance class (D):(A): compounds comprising two rings which are directly linked to one another and are selected from phenylene-1,4-diyl, pyrimidine-2,5-diyl, pyridine-2,5-diyl and pyridazine-2,5-diyl with the proviso that at least one of these rings is a nitrogen heterocycle;(B): compounds comprising three rings selected from phenylene-1,4-diyl, two of the rings being directly linked to one another and the third ring being linked to one of the other two rings via an -OC(=O)- or -C(=O)-group, with the proviso that at least one of the three rings is fluorophenylene-1,4-diyl or ortho-difluorophenylene-1,4-diyl;(C): compounds comprising three rings which are directly linked to one another and are selected from phenylene-1,4-diyl, pyrimidine-2,5-diyl, pyridine-2,5-diyl and pyridazine-2,5-diyl with the proviso that at least one of these rings is a nitrogen heterocycle;(D): compounds comprising mesogenic groups suitable as components of liquid crystal mixtures.

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001"/>(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup

The invention relates to isoxazolo-pyridazine compounds, in particular those of formula I as described above and to a pharmaceutically acceptable salts thereof, having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the treatment of cognitive disorders like Alzheimer's disease.

The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

A thiazole derivative of the formula (I): wherein R is a 1-optionally substituted-6-oxo-1,6-dihydro-3-pyridazinyl, R′ is an optionally substituted phenyl, and R² is hydrogen, a group of the formula (i): wherein R⁴ is hydrogen, lower alkyl or lower alkenyl, and R⁵ is hydrogen, optionally substituted lower alkyl, acyl, cyclo(lower)alkyl, lower alkenyl, optionally substituted aryl or heterocyclic, or a group of the formula (ii): wherein X is oxygen or sulfur, R⁸ is hydrogen or lower alkyl, R⁹ is hydrogen, optionally substituted lower alkyl, cyclo(lower)alkyl, lower alkoxy or mono- or di-lower alkylamino or R⁸ and R⁹ may combine together to form optionally substituted saturated N-containing heterocyclic, or a salt thereof.

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.

Disclosed are compounds and pharmaceutically acceptable salts of Formula I

wherein A, Q₁, Q₂, Q₃, R₃₁, and R₄₁ are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

The present invention provides a composition including an association complex of a pharmaceutical composition and one or more polyethylene-polypropylene glycol block co-polymers (poloxamers). The pharmaceutical composition may include a member selected from the group consisting of (a) an association complex of an eprosartan composition including eprosartan or a pharmaceutically acceptable salt of eprosartan and (b) the non-zwitterionic compound 2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5 dihydro-3H-pyridazino (4,5-b)indol-1-yl)-N,N-dimethylacetamide (NZ).

A liquid crystal compound selected from a group of compounds represented by formula (a):

wherein Ra and Rb are each independently alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons, alkenyl having 2 to 10 carbons, alkenyloxy having 2 to 9 carbons, fluoroalkyl having 1 to 10 carbons or fluoroalkoxy having 1 to 9 carbons; ring A¹, ring A² and ring A³ are each independently trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, trans-tetrahydropyran-2,5-diyl, 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,3-difluoro-1,4-phenylene, 2,5-difluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene, pyridine-2,5-diyl, 6-fluoropyridine-2,5-diyl or pyridazine-2,5-diyl; Z¹, Z² and Z³ are each independently a single bond, —(CH₂)₂—, —CH═CH—, —C≡C—, —CH₂O, —OCH₂—, —COO—, —OCO—, —OCF₂—, —CF₂O—, —CH₂CH₂OCF₂— or —CF₂OCH₂CH₂—; l, m and n are each independently 0, 1 or 2, provided that l+m+n is 0, 1, 2 or 3; one of X¹ and X² is fluorine, and the other is chlorine; Q is

and atoms comprising the compound each may be an isotope thereof.

By searching various compounds having an inhibiting activity against IL-12/IL-23 production, the present invention provides a pharmaceutical composition or a therapeutic or preventive agent for diseases related to IL-12/IL-23 excessive production each of which comprises the compound(s) of the present invention.

More specifically, the present invention provides an imidazopyridazine compound having an inhibiting activity against IL-12/IL-23 production or pharmaceutically acceptable salts thereof; and a useful pharmaceutical composition or a useful therapeutic or preventive agent for diseases related to IL-12/IL-23 excessive production each of which comprises said compound or pharmaceutically acceptable salts thereof.

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

The invention relates to a liquid crystal aligning agent, a liquid crystal aligning film and a liquid crystal display unit. The liquid crystal aligning film with less residual DC can be obtained through the liquid crystal aligning agent containing following polyamide acids which is obtained from diamines represented by the formula (P) or from reaction between mixture of diamines represented by the formula (P) and other diamines and tetracaboxylic dianhydride. Moreover, the liquid crystal display unit without burn-in can be obtained through the liquid crystal aligning film. Ring P is pyridine-2, 5-diyl, pyridazine-3,6-diyl, pyrimidine-2, 5-diyl or pyrazine-2, 5-diyl, and K equals 0 or 1, wherein when K equals 0, ring P is pyridine-2, 5-diyl, pyrimidine-2, 5-diyl, and the amino bonding position in the ring is 5.

The present invention relates to compounds of formula (I) wherein R1, Ra, Rb and Z have the meaning given in claim 1, and their use in the prophylaxis and treatment of diseases.

The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formula I) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

A cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytoines. The compound having a structure represented by the following formula (I):

wherein A represents an optionally substituted trivalent group which is benzene, pyrimidine, pyrrole, pyridine, pyridazine, furan, thiopene, pyrazole, imidazole, isoxazole or isothiazole; R¹ represents an aryl or a heteroaryl group, which is unsubstituted or substituted; R² represents a heteroaryl group which is unsubtituted or substituted; and R³ represents a cyclic tertiary amino group, or a pharmacologically acceptable salt of the compound.

This invention relates to 4-substitued phenyl pyridazine chemical compound and its weed killing reactivity. The chemical compounds (I)(II) have high weed killing reactivity. It can effectively kill the one-year ruderal and broad-leave weed. There after, R1: H, alkyl, alkoxyl, alkylogen, alkylogen oxide, halogen and etc; R2, H, alkyl, alkoxyl, phenyl alkoxyl, hydroxyl phenyl, alkoxyl alkyl, alkylogen, alkylogen alkoxyl, nitryl, cyan, alkyl amine, dialkyl, acetylamino and etc; R3:H, phenyl, hydroxyl phenyl, alkoxyl, alkylogen, halide, alkyl halide and etc; R4: H, benzoxazole, substituted benzoxazole base, benzothiazole and etc; R5: H, alkyl, alkylogen: R6R7: H, alkyl, R6, R7 can be the same or different, n=1 or 2.

The present disclosure relates to tirazalopyridazine protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.

A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.